InspireMD (NYSE:NSPR) Trading Up 0% – Still a Buy?

InspireMD, Inc. (NYSE:NSPR)’s share price rose 0% during mid-day trading on Wednesday . The company traded as high as $0.7231 and last traded at $0.72. Approximately 39,792 shares traded hands during mid-day trading, a decline of 75% from the average session volume of 156,890 shares. The stock had previously closed at $0.7199.

Wall Street Analyst Weigh In

NSPR has been the topic of a number of recent analyst reports. Lake Street Capital set a $4.00 price objective on shares of InspireMD in a research report on Monday, May 4th. Piper Sandler reaffirmed an “overweight” rating and set a $3.00 price objective (down from $4.00) on shares of InspireMD in a research report on Tuesday, May 5th. Three analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $4.50.

InspireMD Stock Performance

The firm has a market cap of $34.70 million, a price-to-earnings ratio of -0.99 and a beta of 0.81. The firm has a 50-day moving average price of $0.74 and a two-hundred day moving average price of $1.23.

Insiders Place Their Bets

In related news, CEO Marvin Slosman acquired 21,000 shares of the business’s stock in a transaction on Tuesday, May 12th. The shares were bought at an average price of $1.20 per share, with a total value of $25,200.00. Following the completion of the acquisition, the chief executive officer owned 3,556,658 shares in the company, valued at $4,267,989.60. This trade represents a 0.59% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have purchased a total of 51,000 shares of company stock worth $54,700 over the last 90 days. 24.98% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. XTX Topco Ltd purchased a new stake in InspireMD in the fourth quarter valued at $30,000. Renaissance Technologies LLC purchased a new position in shares of InspireMD during the first quarter worth about $29,000. Virtu Financial LLC purchased a new position in shares of InspireMD during the fourth quarter worth about $31,000. Creative Planning acquired a new stake in shares of InspireMD during the second quarter worth about $44,000. Finally, Legato Capital Management LLC acquired a new stake in shares of InspireMD during the fourth quarter worth about $48,000. 44.78% of the stock is owned by hedge funds and other institutional investors.

InspireMD Company Profile

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.